BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 38014853)

  • 21. Histologic characterization of paediatric mesenchymal neoplasms treated with kinase-targeted therapy.
    Baranov E; Winsnes K; O'Brien M; Voss SD; Church AJ; Janeway KA; DuBois SG; Davis JL; Al-Ibraheemi A
    Histopathology; 2022 Aug; 81(2):215-227. PubMed ID: 35543076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
    DuBois SG; Laetsch TW; Federman N; Turpin BK; Albert CM; Nagasubramanian R; Anderson ME; Davis JL; Qamoos HE; Reynolds ME; Cruickshank S; Cox MC; Hawkins DS; Mascarenhas L; Pappo AS
    Cancer; 2018 Nov; 124(21):4241-4247. PubMed ID: 30204247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1-KMT2A-YAP1 and VIM-KMT2A fusions.
    Massoth LR; Hung YP; Nardi V; Nielsen GP; Hasserjian RP; Louissaint A; Fisch AS; Deshpande V; Zukerberg LR; Lennerz JK; Selig M; Glomski K; Patel PJ; Williams KJ; Sokol ES; Alexander BM; Vergilio JA; Ross JS; Pavlick DC; Chebib I; Williams EA
    Mod Pathol; 2020 Nov; 33(11):2307-2317. PubMed ID: 32461620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma.
    Zhu G; Benayed R; Ho C; Mullaney K; Sukhadia P; Rios K; Berry R; Rubin BP; Nafa K; Wang L; Klimstra DS; Ladanyi M; Hameed MR
    Mod Pathol; 2019 May; 32(5):609-620. PubMed ID: 30459475
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Siozopoulou V; Marcq E; De Winne K; Norga K; Schmitz G; Duwel V; Delvenne P; Smits E; Pauwels P
    Pathol Oncol Res; 2022; 28():1610423. PubMed ID: 35645621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KDM2B-Rearranged Soft Tissue Sarcomas Expand the Concept of BCOR-Associated Sarcoma.
    Motoi T; Hirata M; Kukita Y; Satomi K; Tamura H; Adachi S; Matsushita Y; Horiguchi SI; Hishima T; Ikegami M; Okuma T; Tao K; Arakawa A; Ogawa C; Matsuda K; Ichimura K; Nakamura H; Mori T; Yoshida A
    Mod Pathol; 2023 Nov; 36(11):100317. PubMed ID: 37634866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Diagnosis of uterine sarcomas and rare uterine mesenchymal tumours with malignant potential. Guidelines of the French Sarcoma Group and Rare Gynaecological Tumours].
    Croce S; Devouassoux-Shisheboran M; Pautier P; Ray-Coquard I; Treilleux I; Neuville A; Arnould L; Just PA; Le Frere Belda MA; Averous G; Leroux A; Bataillon G; Mery E; Loussouarn D; Weinbreck N; Le Guellec S; Mishellany F; Morice P; Guyon F; Genestie C
    Bull Cancer; 2024 Jan; 111(1):97-116. PubMed ID: 37806863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unclassified mesenchymal sarcoma with NTRK1-KHDRBS1 gene fusion: a case report of long-term tumor-free survival with crizotinib treatment.
    Chen W; Wang H; Jiang D; Luan L; Zhou Y; Hou Y
    World J Surg Oncol; 2021 Apr; 19(1):136. PubMed ID: 33941195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Soft tissue tumors characterized by a wide spectrum of kinase fusions share a lipofibromatosis-like neural tumor pattern.
    Kao YC; Suurmeijer AJH; Argani P; Dickson BC; Zhang L; Sung YS; Agaram NP; Fletcher CDM; Antonescu CR
    Genes Chromosomes Cancer; 2020 Oct; 59(10):575-583. PubMed ID: 32506523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary cardiac undifferentiated pleomorphic sarcoma is associated with TP53 mutation during lack of MDM2 amplification, and targeted sequencing analysis reveals potentially actionable targets.
    Cui Y; Han L; Shang J; Fang W; Zhao M; Chen D; Liu H
    Hum Pathol; 2022 May; 123():113-122. PubMed ID: 35181378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group.
    Croce S; Devouassoux-Shisheboran M; Pautier P; Ray-Coquard I; Treilleux I; Neuville A; Arnould L; Just PA; Belda MALF; Averous G; Leroux A; Mery E; Loussouarn D; Weinbreck N; Le Guellec S; Mishellany F; Morice P; Guyon F; Genestie C
    Gynecol Oncol; 2022 Nov; 167(2):373-389. PubMed ID: 36114030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
    J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone.
    Ali NM; Niada S; Brini AT; Morris MR; Kurusamy S; Alholle A; Huen D; Antonescu CR; Tirode F; Sumathi V; Latif F
    J Pathol; 2019 Feb; 247(2):166-176. PubMed ID: 30281149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel fusion sarcomas including targetable NTRK and ALK.
    Chen T; Wang Y; Goetz L; Corey Z; Dougher MC; Smith JD; Fox EJ; Freiberg AS; Flemming D; Fanburg-Smith JC
    Ann Diagn Pathol; 2021 Oct; 54():151800. PubMed ID: 34464935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of
    Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
    Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report.
    Kubota Y; Kawano M; Iwasaki T; Itonaga I; Tsumura H; Kaku N; Tanaka K
    Medicine (Baltimore); 2023 Dec; 102(49):e36232. PubMed ID: 38065851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 immunohistochemical analysis of fusion-positive uterine sarcomas.
    Mohammad N; Stewart CJR; Chiang S; Turashvili G; Dickson BC; Ng TL; Köbel M; McCluggage WG; Croce S; Lee CH
    Histopathology; 2021 May; 78(6):805-813. PubMed ID: 33118176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma.
    Kao YC; Fletcher CDM; Alaggio R; Wexler L; Zhang L; Sung YS; Orhan D; Chang WC; Swanson D; Dickson BC; Antonescu CR
    Am J Surg Pathol; 2018 Jan; 42(1):28-38. PubMed ID: 28877062
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Bastos AU; de Jesus AC; Cerutti JM
    Eur J Endocrinol; 2018 Jan; 178(1):83-91. PubMed ID: 29046324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.